KRYS vs. BCRX, ITOS, ALEC, TSHA, NK, BGNE, TEVA, GMAB, SMMT, and VTRS
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include BioCryst Pharmaceuticals (BCRX), iTeos Therapeutics (ITOS), Alector (ALEC), Taysha Gene Therapies (TSHA), NantKwest (NK), BeiGene (BGNE), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Viatris (VTRS). These companies are all part of the "medical" sector.
Krystal Biotech (NASDAQ:KRYS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.
Krystal Biotech presently has a consensus price target of $196.75, suggesting a potential downside of 2.40%. BioCryst Pharmaceuticals has a consensus price target of $14.17, suggesting a potential upside of 78.87%. Given BioCryst Pharmaceuticals' higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 14 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 19 mentions for Krystal Biotech and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.09 beat Krystal Biotech's score of 0.76 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.
BioCryst Pharmaceuticals received 196 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 67.22% of users gave Krystal Biotech an outperform vote while only 66.53% of users gave BioCryst Pharmaceuticals an outperform vote.
Krystal Biotech has a net margin of 63.73% compared to BioCryst Pharmaceuticals' net margin of -38.18%. Krystal Biotech's return on equity of 1.99% beat BioCryst Pharmaceuticals' return on equity.
Krystal Biotech has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.
Krystal Biotech has higher earnings, but lower revenue than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Krystal Biotech beats BioCryst Pharmaceuticals on 14 of the 19 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
Free KRYS Stock Alerts